ClinicalTrials.gg
Active, not recruitingNCT04108156PagodaUpdated Oct 8, 2026

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

A Phase 3 interventional study of PDS Implant Pre-Filled with 100 mg/mL Ranibizumab and Intravitreal Ranibizumab 0.5 mg Injection in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Active, not recruiting at 89 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

How we know

Updated Oct 8, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
672
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.

Enrollment
5th of 25
672 · median 377
Started
2019
with 1 other
Phase 3
14 of 28
none open now
Registered
12th of 28
by date

Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 5th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2019, is one of 14 in phase 3, and was the 12th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Macular Edema by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibizumab 0.5 milligrams (mg) every 4 weeks (Q4W).

The substudy will evaluate safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main study, GR40550. Up to 100 participants from the main study will be enrolled and followed for a maximum of 72 weeks post-re-implantation in the substudy.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • Port Delivery System
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age ≥18 years at time of signing form (ICF)
  • Documented diagnosis of diabetes mellitus (Type 1 or Type 2)
  • (HbA1c) level of ≤10% within 2 months prior to screening or at screening

Study eye

  • Macular thickening secondary to DME involving the center of the fovea with CST ≥325 micrometer (µm) on SD-OCT at screening
  • BCVA score of 78 to 25 letters (20/32 to 20/320 approximate Snellen equivalent)

Exclusion Criteria:

  • High-risk PDR
  • Active intraocular inflammation (grade trace or above)
  • Suspected or active ocular or periocular infection of either eye
  • Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a patient's participation in the study
  • Cerebrovascular accident or myocardial infarction within 6 months prior to randomization
  • Atrial fibrillation diagnosis or worsening within 6 months prior to randomization
  • Uncontrolled blood pressure

Substudy:

Inclusion Criteria:

  • Having experienced a septum dislodgement in the original implant while in the main study or after exiting the main study
  • Sufficiently clear ocular media and adequate pupillary dilation to allow for analysis and grading by central reading center

Exclusion Criteria (Cohort 1 Only):

  • Recent history (in the last 3 months prior to enrollment) of other disease, other non-diabetic metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of ranibizumab or surgical placement of the PDS implant; that might affect interpretation of the results of the study; or that renders the participant at high risk for treatment complications
  • Active cancer within the last 12 months, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer
  • Current systemic treatment for a confirmed active systemic infection
  • Participation in an trial that involves treatment with any drug or device (with the exception of vitamins and minerals or enrollment in Study GR40550) within 6 months prior to enrollment
  • Use of antimitotic or antimetabolite therapy within 30 days

Ocular Exclusion Criteria for Study Eye:

  • Any ocular condition that may render the participant at high risk for surgical or treatment complications
  • Intraocular surgery (including cataract surgery) within 1 month preceding the enrollment visit
  • Any use of medicated intraocular implants (other than the PDS implant), at any time prior to enrollment
  • History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 months prior to the enrollment visit
  • Any concurrent ocular condition that would require surgical intervention during the study to prevent or treat visual loss
  • Concurrent conjunctival, tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye (e.g., scarring, thinning, mass) that may affect the refill-exchange procedure of the PDS implant
  • Ongoing ocular complications that might affect participant safety Ocular Exclusion Criteria for Either Eye
  • Suspected or active ocular or periocular infection (e.g., infectious conjunctivitis or endophthalmitis)
  • Any history of uveitis
  • Active blepharitis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
672 participants (actual)

Study arms

  • Experimental
    PDS Arm

    Participants randomized to the PDS arm will receive IVT ranibizumab injection Q4W (loading phase) and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval Q24W thereafter.

    Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab · Drug: Ranibizumab refill exchange

  • Active comparator
    Intravitreal Arm

    Participants randomized to the intravitreal arm will receive IVT ranibizumab injection Q4W until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q24W thereafter.

    Drug: Intravitreal Ranibizumab 0.5 mg Injection · Drug: Ranibizumab refill exchange

  • Experimental
    Substudy: Cohort 1

    Participants will undergo re-implantation with the updated PDS implant (pre-filled with ranibizumab 100 milligrams per milliliter \[mg/mL\]) on Day 1 (or enrollment visit) and then will have two refill-exchanges (ranibizumab 100 mg/mL) Q24W up to 48 weeks.

    Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab · Drug: Ranibizumab refill exchange

  • Experimental
    Substudy: Cohort 2a

    Participants who received an updated PDS implant, have \< 24 weeks post-re-implantation follow-up and no scheduled refill-exchange visit in the main study, will undergo two refill-exchange procedures (ranibizumab 100 mg/mL) Q24W, post main study re-implantation visit.

    Drug: Ranibizumab refill exchange

  • Experimental
    Substudy: Cohort 2b

    Participants who received an updated PDS implant, have \< 48 weeks post-re-implantation follow-up and one refill exchange visit in the main study, regardless of whether the refill exchange was administered or the visit was missed, will undergo one refill-exchange procedure (ranibizumab 100 mg/mL) Q24W, post main study re-implantation visit.

    Drug: Ranibizumab refill exchange

Interventions

  • DrugPDS Implant Pre-Filled with 100 mg/mL Ranibizumab

    Will be administered as per the schedule described in individual arm.

  • DrugRanibizumabStudies of RanibizumabRanibizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Will be administered as per the schedule described in individual arm.

  • DrugRanibizumab refill exchange

    Will be administered as per the schedule described in individual arm.

06

What researchers measure

Primary outcomes

  1. Change in BCVA Score From Baseline Averaged Over Weeks 60 and 64 as Measured Using the ETDRS Chart in the Efficacy Population Using a Treatment Policy Strategy for all Intercurrent Events

    BCVA = Best-Corrected Visual Acuity ETDRS = Early Treatment Diabetic Retinopathy Study A vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind.

    Time frame: Baseline to Week 64

  2. Substudy: Number of Participants With Ocular and Systemic (Non-ocular) Adverse Events (AEs) and Severity of Ocular and Systemic AEs

    Time frame: Baseline to Week 72

  3. Substudy: Number of Participants With Adverse Events of Special Interests (AESIs) and Severity of AESIs

    Time frame: Baseline to Week 72

  4. Substudy: Duration of AESIs

    Time frame: Baseline to Week 72

  5. Substudy: Number of Participants With Ocular AESIs and Severity of Ocular AESIs During the Post-operative Period

    Time frame: Up to Day 37 post re-implantation

  6. Substudy: Number of Participants With Ocular AESIs and Severity of Ocular AESIs During the Follow-up Period

    Time frame: > 37 days post-implantation (up to approximately 72 weeks)

  7. Substudy: Duration of Ocular AESIs During the Post-operative Period

    Time frame: Up to Day 37 post re-implantation

  8. Substudy: Duration of Ocular AESIs During the Follow-up Period

    Time frame: > 37 days post-implantation (up to approximately 72 weeks)

  9. Substudy: Number of Participants With Adverse Device Effects (ADEs) and Severity of ADEs

    Time frame: Baseline to Week 72

  10. Substudy: Number of Participants With Anticipated Serious ADEs

    Time frame: Baseline to Week 72

  11. Substudy: Duration of Serious ADEs

    Time frame: Baseline to Week 72

  12. Substudy: Number of Device Deficiencies

    Time frame: Baseline to Week 72

Secondary outcomes

  1. Change in BCVA Score From Baseline Averaged Over Weeks 60 and 64 as Measured With Use of the ETDRS Chart in the Modified Intent-to-treat (mITT) Population Using a Treatment Policy Strategy for All Intercurrent Events

    ETDRS-DRSS = ETDRS Diabetic Retinopathy Severity Scale

    Time frame: Baseline to Week 64

  2. Change in BCVA Score From Baseline Averaged Over Weeks 60 and 64 as Measured With Use of the ETDRS Chart in the mITT Population Using a Hypothetical Strategy for All Intercurrent Events

    Time frame: Baseline to Week 64

  3. Percentage of Participants With a ≥2-step Improvement From Baseline on the ETDRS-DRSS at Week 64 in the Efficacy Population

    Time frame: Baseline to Week 64

  4. Percentage of Participants With a ≥2-step Improvement From Baseline on the ETDRS-DRSS at Week 64 in the mITT population

    Time frame: Baseline to Week 64

  5. Change from Baseline in BCVA as Measured on the ETDRS Chart Over Time

    Time frame: Baseline up to Week 120

  6. Percentage of Participants Who Lose <15, <10, and <5 letters in BCVA From Baseline Over Time

    Time frame: Baseline up to Week 120

  7. Percentage of Participants Who Gain ≥15, ≥10, ≥5, ≥0 Letters in BCVA From Baseline Over Time

    Time frame: Baseline up to Week 120

  8. Percentage of Participants With a BCVA Snellen Equivalent of 20/40 or Better Over Time

    Time frame: Baseline up to Week 120

  9. Percentage of Participants With a BCVA Snellen Equivalent of 20/200 or Worse Over Time

    Time frame: Baseline up to Week 120

  10. Percentage of Participants With a ≥2-step Improvement From Baseline on the ETDRS-DRSS Over Time

    Time frame: Baseline up to Week 120

  11. Percentage of Participants With a ≥3-step Improvement From Baseline on the ETDRS-DRSS Over Time

    Time frame: Baseline up to Week 120

  12. Time to ≥2-step Worsening From Baseline on the ETDRS-DRSS

    Time frame: Baseline up to Week 120

  13. Time to ≥3-step Worsening From Baseline on the ETDRS-DRSS

    Time frame: Baseline up to Week 120

  14. Change From Baseline in ETDRS-DRSS Score Over Time

    Time frame: Baseline up to Week 120

  15. Change From Baseline in Central Subfield Thickness (CST) as Measured on Spectral Domain Optical Coherence Tomography (SD-OCT) Over Time

    Time frame: Baseline up to Week 120

  16. Change From Baseline in Total Macular Volume as Measured on SD-OCT Over Time

    Time frame: Baseline up to Week 120

  17. Percentage of Participants With Absence of Intraretinal Fluid (IRF) Over Time (IRF as Measured in the Central 1 mm Subfield)

    Time frame: Baseline up to Week 120

  18. Percentage of Participants With Absence of Subretinal Fluid (SRF) Over Time (SRF as Measured in the Central 1 mm Subfield)

    Time frame: Baseline up to Week 120

  19. Percentage of Participants With Absence of IRF and SRF Over Time

    Time frame: Baseline up to Week 120

  20. Percentage of Participants With Absence DME (Defined as CST ≥325 μm on SD-OCT) Over Time

    DME = diabetic macular edema

    Time frame: Baseline up to Week 120

  21. Time to PDR (Defined as a Score ≥60 on the ETDRS-DRSS)

    PDR = proliferative diabetic retinopathy

    Time frame: Baseline up to Week 120

  22. Percentage of Participants Who do not Undergo Supplemental Treatment With IVT Ranibizumab Within Each Refill-exchange Interval

    Time frame: Baseline up to Week 120

  23. Percentage of Participants Who Report Preferring PDS Treatment Compared With IVT Ranibizumab Treatment

    As measured by the PDS patient preference questionnaire (PPPQ) at Week 64 among participants in the PDS arm efficacy population, mITT population

    Time frame: Baseline to Week 64

  24. Percentage of Participants Who Report Preferring PDS Treatment Compared With IVT Ranibizumab Treatment, as Measured by the PPPQ at Week 64

    Participants in a subset of patients with bilateral disease who are simultaneously receiving ranibizumab via study eye PDS implant and fellow eye IVT injection.

    Time frame: Baseline to Week 64

  25. Participant-reported Vision-related Functioning and Health-Related Quality of Life (HRQoL) Among Participants in Both Treatment Arms, as Measured by Changes From Baseline

    As measured by in the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) composite score and Near Activities, Distance Activities, and Driving subscale scores

    Time frame: , Baseline Week 48, Week 96

  26. Participant-reported Vision-related Functioning and HRQoL, as Measured by the Proportion of Participants With a ≥ 4-Point Improvement From Baseline in the NEI VFQ-25 Composite Score at Weeks 48 and 96 Among Participants in Both Treatment Arms

    Time frame: Baseline, Week 48, Week 96

  27. Incidence and Severity of Ocular AEs

    Time frame: Baseline to Week 120

  28. Incidence and Severity of Non-ocular AEs

    Time frame: Baseline up to Week 120

  29. Incidence, Severity, and Duration of AEs of Special Interest

    Time frame: Baseline up to Week 120

  30. Serum Concentration of Ranibizumab Observed Over Time

    Time frame: Baseline up to Week 120

  31. PK Parameter: Value Area Under the Concentration- Time Curve Over 24 weeks (AUC24W)

    Time frame: Baseline to Week 24

  32. PK Parameter: Maximum Serum Concentration (Cmax)

    Time frame: Baseline up to Week 120

  33. PK Parameter: Minimum Serum Concentration (Cmin)

    Time frame: Baseline up to Week 120

  34. Time of Maximum Observed Serum Concentration (Tmax) After PDS Implant Insertion

    Time frame: Baseline up to Week 120

  35. Prevalence of Anti-drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study

    Time frame: Baseline up to Week 120

  36. Prevalence of Neutralizing Antibodies at Baseline and Incidence of Neutralizing Antibodies During the Study

    Time frame: Baseline up to Week 120

  37. Reported Incidence of Device Deficiencies

    Time frame: Baseline up to Week 120

  38. Incidence and Severity of Ocular AEs

    Time frame: Baseline up to Week 120

  39. Incidence, Severity, and Duration of AESIs

    Time frame: Baseline up to Week 120

  40. Incidence, Severity, and Duration of Ocular AESIs During the Postoperative Period (up to 37 Days After Initial Implantation) and Follow-up Period (> 37 days After Implantation Surgery)

    Time frame: Baseline up to Week 120

  41. Incidence and Severity of ADEs

    Time frame: Baseline up to Week 120

  42. Incidence, Causality, Severity, and Duration of Anticipated Serious ADEs

    Time frame: Baseline up to Week 120

  43. Substudy: Number of Participants With Ocular AESIs and Severity of Ocular AESIs After Refill-exchange Procedure

    Time frame: Up to approximately 72 weeks

  44. Substudy: Duration of AESIs After Refill-exchange Procedure

    Time frame: Up to approximately 72 weeks

  45. Substudy: Number of Participants With ADEs and Severity of ADEs After Refill-exchange Procedure

    Time frame: Up to approximately 72 weeks

  46. Substudy: Number of Participants With Anticipated Serious ADEs After Refill-exchange Procedure

    Time frame: Up to approximately 72 weeks

  47. Substudy: Duration of Serious ADEs After Refill-exchange Procedure

    Time frame: Up to approximately 72 weeks

  48. Substudy: Number of Device Deficiencies After Refill-exchange Procedure

    Time frame: Up to approximately 72 weeks

07

Study locations

89 sites
08

References and documents

Publications

  • Khanani AM, Campochiaro PA, Graff JM, Marcus DM, Miller D, Mittra RA, Regillo C, Sheth VS, Bobbala A, Gune S, Lin S, Quezada-Ruiz C, Malhotra V. Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. JAMA Ophthalmol. 2025 Apr 1;143(4):326-335. doi: 10.1001/jamaophthalmol.2025.0006. PubMed 40048197 ↗
  • Stockwell AD, Chang MC, Mahajan A, Forrest W, Anegondi N, Pendergrass RK, Selvaraj S, Reeder J, Wei E, Iglesias VA, Creps NM, Macri L, Neeranjan AN, van der Brug MP, Scales SJ, McCarthy MI, Yaspan BL. Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema. PLoS Genet. 2023 Aug 16;19(8):e1010609. doi: 10.1371/journal.pgen.1010609. eCollection 2023 Aug. PubMed 37585454 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Jul 2027, 93 months after the start.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's planned 93 months is above that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2019
First posted
Sep 30, 2019
StartActual
Sep 30, 2019
Primary completionEst.
Jul 20, 2027
CompletionEst.
Jul 20, 2027
Results delay requested
Sep 7, 2023
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • The Retina Care Center · Baltimore, United States
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    1 site added
    Show site
    • The Retina Care Center · Baltimore, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04108156
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 30, 2019
Start date
Sep 30, 2019
Primary completion
Jul 20, 2027 (estimated)
Completion
Jul 20, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion